Showing 1–12 of 141 resultsSorted by latest
Pharma & Biotech
Gross margin increased to 83.5%, helped by better production costs and product mix, though partly reduced by lower prices.
GE HealthCare Technologies (GEHC) reported revenue of $4.8 billion in Q1 FY25, up 3% on a reported basis and 4% organically year-over-year, with growth across all segments and strong performance in the U.S.
n Q1, Roche (ROG) Pharma delivered CHF 11.9 billion in sales, with an 8% growth at constant exchange rates. The US, Europe, and international markets all showed strong growth, with Japan returning to growth as well. Pharma volumes increased by 13%.
In MedTech, sales grew 4.1%, driven by strong results from Abiomed, Shockwave, surgical vision, and wound closure. Important milestones included the upgrade of Impella’s clinical guidelines and the launch of
Shockwave’s new device for peripheral artery disease
The Chemical and Advanced Materials segment saw a 2% decline, mainly due to a high-teens drop in China related to Lunar New Year timing. Diagnostics and Clinical grew 7%, driven by strong results in the Americas and Europe.
RPRX delivered strong performance in 2024, reporting Portfolio Receipts of $2.8 billion, which was at the high end of its guidance range.
ADMA reported total revenue of $426.5 million for 2024, up 65% from $258.2 million in 2023, mainly due to increased sales of ASCENIV and strong demand from physicians, payers, and patients.
CVS Health reported nearly $98 billion in fourth-quarter revenue, up 4% from the previous year, mainly due to growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments.
The company continues to invest in disruptive innovation while maintaining tight control over costs to ensure long-term competitiveness.
The colocation business remained robust across all three operating regions, while interconnection revenue outpaced colocation growth.
AMGN remains focused on long-term growth while navigating regulatory and political changes, falling net prices, and the loss of exclusivity on certain products.
United Therapeutics (UTHR) has started a three-year plan focused on key clinical and regulatory events.